Factors affecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG

Pakistan Journal of Medical Sciences

Volumn 30, Issue 2, 2014, Pages 326-330

  Khan, Muhammad Kashif ^a   Ahmed, Irfan ^a   Raza, Syed Johar ^a  

^a SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL AND RESEARCH CENTRE   (Pakistan)

Author keywords

BCG; High grade; Non muscle invasive bladder cancer; Progression; Recurrence

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; ASIAN; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; CYSTOSCOPY; DRUG RESPONSE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; RECURRENCE RISK; RETROSPECTIVE STUDY; SMOKING; TUMOR LOCALIZATION; TUMOR VOLUME; CANCER GRADING; CANCER LOCALIZATION; CANCER PATIENT; CANCER SIZE; MEDICAL SOCIETY; POPULATION RESEARCH; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE;

EID: 84894617479     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: 10.12669/pjms.302.4117     Document Type: Article

References (25)

1. Ploeg M, Aben KKH, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27(3):289-293. DOI:10.1007/s00345-009-0383-3
2. Bhurgri Y, Bhurgri A, Hassan SH, Zaidi SHM, Rahim A, Sankaranarayanan R, et al. Cancer incidence in Karachi, Pakistan: First results from Karachi Cancer Registry. Int J Cancer. 2000;85(3):325-329. DOI: 10.1002/(SICI)1097-0215(20000201)85:3<325::AID-IJC5>3.0.CO;2-J
3. Vaidya A, Soloway MS, Hawke C, Tiguert R, Civantos F. Denovo muscle invasive bladder cancer: is there a change in trend? J Urol. 2001;165(1):47-50. DOI:10.1097/00005392-200101000-00012
4. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983;130(6):1083-1086.
5. Jakse G, Loidl W, Seeber G, Hofstädter F. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J Urol. 1987;137(1):39-43.
6. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al. EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011;59:997-1008. DOI:10.1016/j. eururo.2011.03.017
7. Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93(4):485-490. DOI:10.1111/j.1464-410X.2003.04655.x
8. Duchek M, Johansson R, Jahnson S, Mestad O, Hellström P, Hellsten S, et al. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective randomized, Nordic study. Eur Urol. 2010;57(1):25-31. DOI: 10.1016/j. eururo.2009.09.038
9. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666-675.
10. Ghoneim MA, Abdel-Latif M, el-Mekresh M, Abol-Enein H, Mosbah A, Ashamallah A, et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol. 2008;180(1):121-127. DOI: 10.1016/j. juro.2008.03.024.
11. Segal R, Yafi FA, Brimo F, Tanguay S, Aprikian A, Kassouf W. Prognostic factors andoutcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int. 2012;109(7):1026-1030. DOI: 10.1111/j.1464-410X.2011.10462.x.
12. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22(12):1435-1448.
13. Sauter G, Algaba F, Amin MB, Busch C, Cheville J, Gasser T, et al. Noninvasive urothelial tumours, 'World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs' Eble JN, Sauter G, Epstein IJ and Sesterhenn IA (eds.). Lyon, IARC press, 2004:110-120. ISBN 92 832 2412 4
14. Sobin DH, Wittekind Ch, eds. In: TNM Classification of Malignant Tumours. 6th ed. New York: Wiley Liss, 2002:199-202. ISBN: 0-471-22288-7
15. Machado MT, Esteves MAP, Starling ES, Pompeo ACL, Wroclawski ER. What have we learned after 30 years of BCG intravesical therapy for superficial bladder cancer? Einstein. 2009;7:515-519.
16. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-465.
17. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195-2203. DOI:10.1016/j. juro.2009.07.016
18. Kamat AM, Dickstein RJ, Messetti F, Anderson R, Pretzsch SM, Gonzalez GN, et al. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial. J Urol. 2012;187(3):862-867. DOI: 10.1016/j. juro.2011.10.144.
19. Jancke G, Rosell J, Jahnson S. Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder. Scand J Urol Nephrol. 2011;45(6):388-392. DOI: 10.3109/00365599.2011.590995.
20. Vukomanovic I, Colovic V, Soldatovic I, Hadzi-Djokic J. Prognostic significance of tumor location in highgrade non-muscle-invasive bladder cancer. Med Oncol. 2012;29(3):1916-1920. DOI: 10.1007/s12032-011-9999-4.
21. Palou J, Sylvester RJ, Faba OR, Parada R, Peña JA, Algaba F, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol. 2012;62(1):118-125. DOI: 10.1016/j.eururo.2011.10.029.
22. Lammers RJ, Witjes WP, Hendricksen K, Caris CT, Janzing-Pastors MH, Witjes JA. Smoking status is a risk factor for recurrence after transurethral resection of non-muscleinvasive bladder cancer. Eur Urol. 2011;60(4):713-720. DOI: 10.1016/j.eururo.2011.07.010.
23. Ather MH, Zaidi M. Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables. Urol J. 2009;6(3):189-193.
24. Mansoor M, Ali S, Fasihuddin Q, Baloch MU. Superficial bladder tumours: recurrence and progression. J Coll Physicians Surg Pak. 2011;21(3):157-160. DOI: 03.2011/ JCPSP.157160.
25. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta analysis of published results of randomized clinical trials. J Urol. 2004;171(6):2186-2190.